Description
PBMCs from multiple sclerosis (MS) donors, isolated from leukopak material under cGMP-aligned conditions. Sourced from OrganaBio’s qualified, recallable donor pool with 14-marker infectious disease screening per 21 CFR 1271 and high-resolution NGS HLA typing. Disease-state PBMCs are supplied for research/discovery use only. Best fit: T cell autoreactivity assays, remyelination drug screening, and neuroinflammation biomarker discovery.
LeukoPAC-D-PBMC – Disease-State Cryopreserved Peripheral Blood Mononuclear Cells
LeukoPAC-D-PBMC delivers cryopreserved peripheral blood mononuclear cells from donors with documented disease conditions, collected under IRB-approved protocols. Disease-state PBMCs are essential for cell therapy development because manufacturing processes and assays optimized using healthy donor cells frequently fail to translate to cells from patients in the target population.
MS donor PBMCs reflect the autoreactive T cell phenotypes and Th17 skewing characteristic of active and remission-phase disease.
Why Disease-State PBMCs
Patients eligible for cell therapies have often been treated with multiple rounds of chemotherapy or other interventions, which can compromise T cell functionality and shift cellular phenotypes in ways that healthy donor controls do not capture. Process development on disease-state PBMCs allows manufacturing teams and assay developers to validate workflows against material that reflects the immune biology of the patient population they intend to treat.
Available Indications
This product is sourced from donors with documented multiple sclerosis (MS). OrganaBio’s disease-state donor pool spans 24 autoimmune and chronic inflammatory indications including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, type 1 diabetes, Crohn’s disease, ulcerative colitis, psoriasis, and others. Contact the scientific team to confirm availability and lot status for your specific indication.
Documentation
Each sample is supported by comprehensive documentation including disease history, treatment background, inclusion and exclusion criteria compliance, and demographic profiles. Every lot ships with a Certificate of Analysis. Donors are enrolled under IRB-approved protocols with verified clinical diagnosis.
Configuration
Standard configuration: 1.0×10⁷ cells per vial, cryopreserved, stored at <−150°C in liquid nitrogen vapor phase. Custom cell counts, fresh format, and specific donor criteria available on request. Cells are for preclinical research use only and not for use in humans.
For background on disease-state donor samples in cell therapy development, see Why Disease-State Donor Samples Are Essential for Cell Therapy Development.
{“@context”:”https://schema.org”,”@type”:”Product”,”name”:”LeukoPAC-D-PBMC – Multiple Sclerosis Disease-State Cryopreserved PBMCs”,”description”:”Cryopreserved peripheral blood mononuclear cells from donors with documented multiple sclerosis (MS). Collected under IRB-approved protocols. Used for neuroimmunology research, T cell autoreactivity assays, and myelin antigen-specific characterization.”,”brand”:{“@type”:”Brand”,”name”:”OrganaBio”},”manufacturer”:{“@type”:”Organization”,”name”:”OrganaBio”,”url”:”https://www.organabio.com”},”category”:”Disease-State Donor Material”,”sku”:”D-PBMC-MS-050″,”image”:”https://www.organabio.com/wp-content/uploads/2026/05/organabio-leukopac-d-pbmc-2026.png”,”offers”:{“@type”:”Offer”,”availability”:”https://schema.org/InStock”,”url”:”https://www.organabio.com/product/leukopak-d-pbmc-ms/”,”seller”:{“@type”:”Organization”,”name”:”OrganaBio”}}}
Frequently Asked Questions
What are Multiple Sclerosis PBMCs used for?
PBMCs from MS donors are used for Th1/Th17 cytokine profiling, myelin antigen-specific T cell expansion assays, disease-modifying therapy mechanism-of-action studies, and neuroinflammation biomarker discovery.
What viability can I expect for cryopreserved Multiple Sclerosis PBMCs?
OrganaBio targets greater than 80% post-thaw viability for cryopreserved disease-state PBMCs. Lot-specific viability data is included in the Certificate of Analysis shipped with every order.
Are Multiple Sclerosis PBMC donors recallable?
Yes. OrganaBio maintains a recallable donor pool for disease-state indications. Donors can be re-collected for longitudinal studies under the same characterization profile. Availability is indication-dependent — contact the scientific team to confirm lot status and re-collection timing.
What HLA and KIR typing is provided for Multiple Sclerosis PBMC donors?
High-resolution NGS HLA typing across HLA-A, B, C, DR, DQ, and DP is performed on every donor. KIR genotyping is included in the standard donor characterization — a differentiator not standard at most competing suppliers.
Are Multiple Sclerosis PBMCs research use only or available at cGMP grade?
Disease-state donor material from OrganaBio is supplied for research and discovery use (RUO). For autoimmune cell therapy programs requiring GMP starting material, the clinical process uses the patient’s own apheresis — not research-use disease-state donors. Contact OrganaBio’s scientific team to discuss your specific program requirements.
{“@context”:”https://schema.org”,”@type”:”FAQPage”,”@id”:”https://www.organabio.com/product/leukopak-d-pbmc-ms/#faq”,”mainEntity”:[{“@type”:”Question”,”name”:”What are Multiple Sclerosis PBMCs used for?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”PBMCs from MS donors are used for Th1/Th17 cytokine profiling, myelin antigen-specific T cell expansion assays, disease-modifying therapy mechanism-of-action studies, and neuroinflammation biomarker discovery.”}},{“@type”:”Question”,”name”:”What viability can I expect for cryopreserved Multiple Sclerosis PBMCs?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”OrganaBio targets greater than 80% post-thaw viability for disease-state PBMCs. Lot-specific viability data is included in the Certificate of Analysis.”}},{“@type”:”Question”,”name”:”Are Multiple Sclerosis PBMC donors recallable?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Yes. OrganaBio maintains a recallable donor pool. Donors can be re-collected for longitudinal studies. Availability is indication-dependent.”}},{“@type”:”Question”,”name”:”What HLA and KIR typing is provided?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”High-resolution NGS HLA typing across HLA-A, B, C, DR, DQ, and DP is performed on every donor. KIR genotyping is included as standard.”}},{“@type”:”Question”,”name”:”Are Multiple Sclerosis PBMCs research use only or available at cGMP grade?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”Disease-state material is research/discovery use only (RUO). For autoimmune cell therapy GMP starting material, the clinical process uses the patient’s own apheresis.”}}]}
